Overview
International law firm McDermott Will & Emery advised Kither Biotech, an Italian biopharmaceutical company developing novel therapies for rare respiratory diseases, in its EUR18.5m Series B funding round. The funding will help accelerate clinical development of the company’s lead product (Kit2014) for the treatment of cystic fibrosis, as well as enable further expansion and diversifying the company’s range of products for the treatment of rare lung diseases.
The group of new investors, led by Claris Ventures and 2Invest, assisted by 3B future health fund and Alef 6, also included some of the existing investors (Cdp Venture Capital Sgr, Italian Angels for Growth, Ersel, Club degli Investitori and Ace Venture) in the round.
The McDermott team advising investor on this transaction was led by Ettore Scandale, partner in charge of the Italian corporate department, supported by associate Stefano Pardini and trainee Matteo Landini.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
